Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 43393 

Potential Commercial Applications: 

• Therapeutics for hypertension 

• Therapeutics for anxiety disorders 

• Therapeutics for sleep disorders 

Development Stage: 

• In vivo data available 

Inventors: George Kunos and 

Alexandros Makriyannis (both of 

NIAAA) 

Intellectual Property: HHS Reference 

No. E–211–2006/0–US–06. 

• U.S. Patent 8,293,724 filed April 6, 

2010, issued October 23, 2012. 

Licensing Contact: Michael 

Shmilovich, Esq, CLP; 301–435–5019; 

shmilovm@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Environmental 

Health Sciences seeks statements of 

capability or interest from parties 

interested in collaborative research to 

further develop and evaluate, please 

contact Peg Koelble, Office of 

Technology Transfer, National Heart, 

Lung and Blood Institute, koelblep@

nhlbi.nih.gov, 301–594–4095. 

Dated: September 7, 2017. 

Michael Shmilovich, 

Senior Licensing and Patenting Manager, 

National Heart, Lung, and Blood Institute, 

Office of Technology Transfer and 

Development. 

[FR Doc. 2017–19590 Filed 9–14–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Chris Kornak, 240–627–3705, chris.

kornak@nih.gov. Licensing information 

and copies of the U.S. patent 

applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office (TTIPO), 5601 Fishers 

Lane, Suite 6D, MSC 9804, Rockville, 

MD 20892, tel: 301–496–2644, fax: 240– 

627–3117. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Recombinant HIV-1 Envelope Proteins 

and Their Use 

Description of Technology: Millions of 

people are infected with HIV-1 

worldwide. In the U.S., there are about 

30,000 new cases of HIV infection 

reported annually. Currently, there are 

effective, anti-retroviral therapeutics 

available to treat or prevent HIV 

infection. However, available antiretroviral therapeutics require life-long 

administration. 

During infection, proteases of the host 

cell cleave gp160 into gp120 and gp41. 

Gp41 is an integral membrane protein, 

while gp120 protrudes from the mature 

virus. Together gp120 and gp41 

aggregate as trimers that make up the 

HIV-1 envelope (‘‘Env’’) spike, which is 

a target for neutralizing antibodies. 

NIAID researchers have constructed a 

recombinant HIV-1 trimer immunogen. 

In particular, the recombinant gp120 

protein in the trimer is stabilized in a 

closed conformation, preventing it from 

binding to CD4. The advantage of the 

closed conformation is that it can 

stabilize the epitopes that bind to 

broadly neutralizing antibodies, 

minimize the binding of gp120 with 

weakly or non-neutralizing antibodies, 

and prevent conformational changes 

induced by CD4 as well as immunogen 

sequestration by CD4 in vivo. Research 

has also indicated that recombinant Env 

ectodomain trimers can induce higher 

neutralizing antibody titers than wild 

type Env trimers in animal models. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• HIV-1 immunogen 

• New methods for isolating broadly 

neutralizing antibodies 

Competitive Advantages: 

• A new strategy in inducing immune 

response against HIV-1 

Development Stage: 

• Pre-Clinical; Proof-of-concept 

studies in nonhuman primate 

models 

Inventors: 

Paolo Lusso, NIAID, NIH 

Peng Zhang, NIAID, NIH 

Publications: Pending. 

Intellectual Property: HHS Reference 

No. E–102–2016/0—PCT Application 

No. PCT/US2017/021573 filed on 03/09/ 

2017. 

Licensing Contact: Chris Kornak, 240– 

627–3705, chris.kornak@nih.gov. 

Collaborative Research Opportunity: 

The Technology Transfer and 

Intellectual Property Office (TTIPO) is 

seeking parties interested in 

collaborative research to further develop 

the technology. In particular, NIAID is 

interested in partnerships utilizing 

vector vaccine platforms for expressing 

these immunogens. 

However, NIAID is willing to discuss 

other applications of this technology. 

For collaboration opportunities, please 

contact Chris Kornak, 240–627–3705, 

chris.kornak@nih.gov. 

Dated: September 7, 2017. 

Suzanne Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–19591 Filed 9–14–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel; Chemical 

Senses Fellowship Review. 

Date: October 11, 2017. 

Time: 12:30 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health. 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 

Contact Person: Sheo Singh, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

6001 Executive Blvd., Room 8351, Bethesda, 

MD 20892, 301–496–8683, singhs@

nidcd.nih.gov. 

mstockstill on DSK30JT082PROD with NOTICES